Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpJAMA Psychiatry
• journal#1
Paul S Appelbaum
No abstract text is available yet for this article.
January 15, 2020: JAMA Psychiatry
#2
(no author information available yet)
No abstract text is available yet for this article.
January 15, 2020: JAMA Psychiatry
#3
Yasmin L Hurd
No abstract text is available yet for this article.
January 15, 2020: JAMA Psychiatry
#4
Amir Sariaslan, Louise Arseneault, Henrik Larsson, Paul Lichtenstein, Seena Fazel
Importance: Key outcomes for persons with psychiatric disorders include subjection to violence and perpetration of violence. The occurrence of these outcomes and their associations with psychiatric disorders need to be clarified. Objective: To estimate the associations of a wide range of psychiatric disorders with the risks of subjection to violence and perpetration of violence. Design, Setting, and Participants: A total of 250 419 individuals born between January 1, 1973, and December 31, 1993, were identified to have psychiatric disorders using Swedish nationwide registers...
January 15, 2020: JAMA Psychiatry
#5
Katherine M Keyes, Noah Kreski
No abstract text is available yet for this article.
January 15, 2020: JAMA Psychiatry
#6
David J Miklowitz, Christopher D Schneck, Patricia D Walshaw, Manpreet K Singh, Aimee E Sullivan, Robert L Suddath, Marcy Forgey Borlik, Catherine A Sugar, Kiki D Chang
Importance: Behavioral high-risk phenotypes predict the onset of bipolar disorder among youths who have parents with bipolar disorder. Few studies have examined whether early intervention delays new mood episodes in high-risk youths. Objective: To determine whether family-focused therapy (FFT) for high-risk youths is more effective than standard psychoeducation in hastening recovery and delaying emergence of mood episodes during the 1 to 4 years after an active period of mood symptoms...
January 15, 2020: JAMA Psychiatry
#7
Kenneth A Feder, Kira E Riehm, Ramin Mojtabai
No abstract text is available yet for this article.
January 15, 2020: JAMA Psychiatry
#8
Christoph U Correll, Robert E Davis, Michal Weingart, Jelena Saillard, Cedric O'Gorman, John M Kane, Jeffrey A Lieberman, Carol A Tamminga, Sharon Mates, Kimberly E Vanover
Importance: Individuals living with schizophrenia are affected by cardiometabolic, endocrine, and motor adverse effects of current antipsychotic medications. Lumateperone is a serotonin, dopamine, and glutamate modulator with the potential to treat schizophrenia with few adverse effects. Objective: To examine the efficacy and safety of lumateperone for the short-term treatment of schizophrenia. Design, Setting, and Participants: This randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted from November 13, 2014, to July 20, 2015, with data analyses performed from August 13 to September 15, 2015...
January 8, 2020: JAMA Psychiatry
#9
Shahram Bahrami, Nils Eiel Steen, Alexey Shadrin, Kevin O'Connell, Oleksandr Frei, Francesco Bettella, Katrine V Wirgenes, Florian Krull, Chun C Fan, Anders M Dale, Olav B Smeland, Srdjan Djurovic, Ole A Andreassen
Importance: People with major psychiatric disorders (MPDs) have a 10- to 20-year shorter life span than the rest of the population, and this difference is mainly due to comorbid cardiovascular diseases. Genome-wide association studies have identified common variants involved in schizophrenia (SCZ), bipolar disorder (BIP), and major depression (MD) and body mass index (BMI), a key cardiometabolic risk factor. However, genetic variants jointly influencing MPD and BMI remain largely unknown...
January 8, 2020: JAMA Psychiatry
#10
Nathaniel P Morris, Robert A Kleinman
No abstract text is available yet for this article.
January 8, 2020: JAMA Psychiatry
#11
Joshua T Kantrowitz
No abstract text is available yet for this article.
January 8, 2020: JAMA Psychiatry
#12
(no author information available yet)
No abstract text is available yet for this article.
January 2, 2020: JAMA Psychiatry
#13
(no author information available yet)
No abstract text is available yet for this article.
January 2, 2020: JAMA Psychiatry
#14
Charles F Zorumski
No abstract text is available yet for this article.
January 2, 2020: JAMA Psychiatry
#15
Adrienne Grzenda, Alik S Widge
No abstract text is available yet for this article.
January 2, 2020: JAMA Psychiatry
#16
Camarin E Rolle, Gregory A Fonzo, Wei Wu, Russ Toll, Manish K Jha, Crystal Cooper, Cherise Chin-Fatt, Diego A Pizzagalli, Joseph M Trombello, Thilo Deckersbach, Maurizio Fava, Myrna M Weissman, Madhukar H Trivedi, Amit Etkin
Importance: Despite the widespread awareness of functional magnetic resonance imaging findings suggesting a role for cortical connectivity networks in treatment selection for major depressive disorder, its clinical utility remains limited. Recent methodological advances have revealed functional magnetic resonance imaging-like connectivity networks using electroencephalography (EEG), a tool more easily implemented in clinical practice. Objective: To determine whether EEG connectivity could reveal neural moderators of antidepressant treatment...
January 2, 2020: JAMA Psychiatry
#17
(no author information available yet)
No abstract text is available yet for this article.
January 2, 2020: JAMA Psychiatry
#18
Neil Krishan Aggarwal
No abstract text is available yet for this article.
December 26, 2019: JAMA Psychiatry
#19
Thomas Nordahl Christensen, Merete Nordentoft, Lene Falgaard Eplov
No abstract text is available yet for this article.
December 26, 2019: JAMA Psychiatry
#20
Kim T Mueser, Susan R McGurk
No abstract text is available yet for this article.
December 26, 2019: JAMA Psychiatry
Fetching more papers... 
